KR101821452B1 - 선택성 사이클린-의존성 키나제 저해제로서 피라졸로-트리아진 유도체 - Google Patents
선택성 사이클린-의존성 키나제 저해제로서 피라졸로-트리아진 유도체 Download PDFInfo
- Publication number
- KR101821452B1 KR101821452B1 KR1020147027812A KR20147027812A KR101821452B1 KR 101821452 B1 KR101821452 B1 KR 101821452B1 KR 1020147027812 A KR1020147027812 A KR 1020147027812A KR 20147027812 A KR20147027812 A KR 20147027812A KR 101821452 B1 KR101821452 B1 KR 101821452B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyrazolo
- amine
- triazine
- triazin
- rti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C(C)(CCN)CCC(C)(CC(C)(*)CC1)N)C1(C)[N+]([O-])=O Chemical compound CC(C(C)(CCN)CCC(C)(CC(C)(*)CC1)N)C1(C)[N+]([O-])=O 0.000 description 4
- OWGCQVDTQVLGAG-GZMMZOGISA-N CC(C)c(cn[n]1c(NCc2ccccc2S(C)=O)n2)c1nc2O[C@H]1CNCCC1 Chemical compound CC(C)c(cn[n]1c(NCc2ccccc2S(C)=O)n2)c1nc2O[C@H]1CNCCC1 OWGCQVDTQVLGAG-GZMMZOGISA-N 0.000 description 1
- FRWNFCDTJYDUHL-UHFFFAOYSA-N CC(C)c(cn[n]1c(N[AlH2])n2)c1nc2S(C)(=O)=O Chemical compound CC(C)c(cn[n]1c(N[AlH2])n2)c1nc2S(C)(=O)=O FRWNFCDTJYDUHL-UHFFFAOYSA-N 0.000 description 1
- UVPAZYFTNVNEBF-UHFFFAOYSA-N CC(C)c(cn[n]1c(OCc2ccccc2)n2)c1nc2S(C)(=O)=O Chemical compound CC(C)c(cn[n]1c(OCc2ccccc2)n2)c1nc2S(C)(=O)=O UVPAZYFTNVNEBF-UHFFFAOYSA-N 0.000 description 1
- FIDVAOGPIORFCW-UHFFFAOYSA-N CC(C)c(cn[n]1c(OCc2ccccc2)n2)c1nc2SC Chemical compound CC(C)c(cn[n]1c(OCc2ccccc2)n2)c1nc2SC FIDVAOGPIORFCW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12157751.4A EP2634190A1 (en) | 2012-03-01 | 2012-03-01 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| EP12157751.4 | 2012-03-01 | ||
| PCT/EP2013/054224 WO2013128028A1 (en) | 2012-03-01 | 2013-03-01 | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140131994A KR20140131994A (ko) | 2014-11-14 |
| KR101821452B1 true KR101821452B1 (ko) | 2018-01-23 |
Family
ID=47757629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147027812A Active KR101821452B1 (ko) | 2012-03-01 | 2013-03-01 | 선택성 사이클린-의존성 키나제 저해제로서 피라졸로-트리아진 유도체 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9567345B2 (https=) |
| EP (2) | EP2634190A1 (https=) |
| JP (1) | JP6182549B2 (https=) |
| KR (1) | KR101821452B1 (https=) |
| CN (1) | CN104350054B (https=) |
| AU (1) | AU2013224848B2 (https=) |
| BR (1) | BR112014021189B1 (https=) |
| CA (1) | CA2865946C (https=) |
| DK (1) | DK2820020T3 (https=) |
| ES (1) | ES2583231T3 (https=) |
| HU (1) | HUE029264T2 (https=) |
| IL (1) | IL234183A (https=) |
| MX (1) | MX347359B (https=) |
| RU (1) | RU2645347C2 (https=) |
| SG (1) | SG11201405129RA (https=) |
| WO (1) | WO2013128028A1 (https=) |
| ZA (1) | ZA201406078B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN106458990B (zh) | 2014-04-04 | 2019-06-07 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| EP3129371B1 (en) * | 2014-04-05 | 2020-07-29 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP6690543B2 (ja) | 2014-10-31 | 2020-04-28 | 宇部興産株式会社 | 置換ジヒドロピロロピラゾール化合物 |
| CN107530329B (zh) * | 2015-03-09 | 2021-10-08 | 奥瑞基尼探索技术有限公司 | 用作CDK抑制剂的吡唑并[1，5-a][1，3，5]三嗪和吡唑并[1，5-a]嘧啶衍生物 |
| CA2989519C (en) | 2015-06-15 | 2023-09-26 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole derivative |
| CN107949563B (zh) * | 2015-06-24 | 2020-06-05 | 库洛维公司 | 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物 |
| BR112019004935A2 (pt) | 2016-09-13 | 2019-06-04 | Allergan, Inc. | composições de toxina clostridial não proteíca estabilizada |
| CN106432249B (zh) * | 2016-09-30 | 2018-12-04 | 陕西科技大学 | 一类吡咯并[2，1-f][1，2，4]三嗪母核化合物的合成及其医药用途 |
| WO2019032720A1 (en) | 2017-08-09 | 2019-02-14 | Sanford Burnham Prebys Medical Discovery Institute | APELIN RECEPTOR AGONISTS AND METHODS OF USE |
| GB201715194D0 (en) | 2017-09-20 | 2017-11-01 | Carrick Therapeutics Ltd | Compounds and their therapeutic use |
| IL276013B2 (en) * | 2018-01-17 | 2024-03-01 | Glaxosmithkline Ip Dev Ltd | Pi4kiiibeta inhibitors |
| EP3774809A1 (en) * | 2018-04-11 | 2021-02-17 | Qurient Co. Ltd. | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives |
| US12606561B2 (en) | 2018-04-11 | 2026-04-21 | Qurient Co., Ltd. | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors |
| EP3774810A1 (en) | 2018-04-11 | 2021-02-17 | Qurient Co. Ltd. | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
| US12022832B2 (en) | 2018-09-12 | 2024-07-02 | The Governing Council Of The University Of Toronto | Compounds and methods for treating nematode infections |
| US11517568B2 (en) | 2018-09-12 | 2022-12-06 | The Governing Council Of The University Of Toronto | Compounds and methods for treating nematode infections |
| CN113677346A (zh) | 2018-11-01 | 2021-11-19 | 希洛斯医药品股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| US12304913B2 (en) | 2018-11-14 | 2025-05-20 | Ube Industries, Ltd. | Dihydropyrrolopyrazole derivative |
| CN110101703B (zh) * | 2019-05-06 | 2021-06-11 | 暨南大学 | Cdk7抑制剂在制备溃疡性结肠炎或结肠癌药物的应用 |
| RU2713152C1 (ru) * | 2019-08-30 | 2020-02-04 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения хронической аллергической крапивницы на фоне описторхоза |
| TW202146416A (zh) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| GB201918541D0 (en) * | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| CN110950871B (zh) * | 2019-12-25 | 2022-05-17 | 陕西师范大学 | 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用 |
| CN116964061A (zh) * | 2020-12-21 | 2023-10-27 | 詹森药业有限公司 | 作为细胞周期蛋白依赖性激酶7（cdk7）抑制剂的三环嘧啶 |
| WO2022182918A1 (en) * | 2021-02-25 | 2022-09-01 | Icahn School Of Medicine At Mount Sinai | Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease |
| US20240254138A1 (en) * | 2021-03-09 | 2024-08-01 | Janssen Pharmaceutica Nv | Tricyclic pyrimidines as cyclin-dependent kinase 7 (cdk7) inhibitors |
| US20250042903A1 (en) * | 2021-06-17 | 2025-02-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Triazine inhibitors of cyclin-dependent kinases |
| WO2023001061A1 (en) * | 2021-07-17 | 2023-01-26 | Jingrui Biopharma Co., Ltd. | Cdk7 selective inhibitors as anticancer agents |
| AU2022318251A1 (en) | 2021-07-29 | 2024-01-25 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
| US20250019382A1 (en) * | 2021-11-23 | 2025-01-16 | Origenis Gmbh | Novel inhibitors of cyclin-dependent kinases |
| CN114181217B (zh) * | 2022-01-10 | 2022-12-27 | 陕西师范大学 | 吡唑并[1,5-a][1,3,5]三嗪衍生物及其盐和在制备抗癌药物中的应用 |
| WO2023175173A1 (en) * | 2022-03-18 | 2023-09-21 | Qurient Co., Ltd. | Cdk7 inhibitors for antiviral treatment |
| CN120712267A (zh) * | 2023-02-21 | 2025-09-26 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077954A2 (en) | 2004-02-11 | 2005-08-25 | Schering Corporation | Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors |
| WO2005082908A1 (en) | 2004-02-25 | 2005-09-09 | Schering Corporation | Pyrazolotriazines as kinase inhibitors |
| WO2010103486A1 (fr) | 2009-03-11 | 2010-09-16 | Centre National De La Recherche Scientifique | Derives de pyrazolo[1,5-a]-1,3,5-triazines, leur preparation et leur application en therapeutique |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
| HUP0200535A3 (en) * | 1999-02-01 | 2002-11-28 | Cv Therapeutics Inc Palo Alto | 2,6,9-trisubstituted purine derivatives inhibitors of cyclin dependent kinase 2 and ikappa-b-alpha and pharmaceutical compositions containing them |
| CZ302122B6 (cs) * | 2009-01-28 | 2010-10-20 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující |
| CZ302711B6 (cs) * | 2009-06-03 | 2011-09-14 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující |
-
2012
- 2012-03-01 EP EP12157751.4A patent/EP2634190A1/en not_active Withdrawn
-
2013
- 2013-03-01 AU AU2013224848A patent/AU2013224848B2/en active Active
- 2013-03-01 US US14/381,146 patent/US9567345B2/en active Active
- 2013-03-01 RU RU2014139705A patent/RU2645347C2/ru active
- 2013-03-01 BR BR112014021189-2A patent/BR112014021189B1/pt active IP Right Grant
- 2013-03-01 CA CA2865946A patent/CA2865946C/en active Active
- 2013-03-01 JP JP2014559259A patent/JP6182549B2/ja active Active
- 2013-03-01 HU HUE13707008A patent/HUE029264T2/en unknown
- 2013-03-01 DK DK13707008.2T patent/DK2820020T3/en active
- 2013-03-01 WO PCT/EP2013/054224 patent/WO2013128028A1/en not_active Ceased
- 2013-03-01 ES ES13707008.2T patent/ES2583231T3/es active Active
- 2013-03-01 SG SG11201405129RA patent/SG11201405129RA/en unknown
- 2013-03-01 MX MX2014010494A patent/MX347359B/es active IP Right Grant
- 2013-03-01 CN CN201380011917.5A patent/CN104350054B/zh active Active
- 2013-03-01 KR KR1020147027812A patent/KR101821452B1/ko active Active
- 2013-03-01 EP EP13707008.2A patent/EP2820020B1/en active Active
-
2014
- 2014-08-19 ZA ZA2014/06078A patent/ZA201406078B/en unknown
- 2014-08-19 IL IL234183A patent/IL234183A/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077954A2 (en) | 2004-02-11 | 2005-08-25 | Schering Corporation | Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors |
| WO2005082908A1 (en) | 2004-02-25 | 2005-09-09 | Schering Corporation | Pyrazolotriazines as kinase inhibitors |
| WO2010103486A1 (fr) | 2009-03-11 | 2010-09-16 | Centre National De La Recherche Scientifique | Derives de pyrazolo[1,5-a]-1,3,5-triazines, leur preparation et leur application en therapeutique |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013128028A8 (en) | 2014-10-02 |
| JP2015511952A (ja) | 2015-04-23 |
| WO2013128028A1 (en) | 2013-09-06 |
| EP2820020A1 (en) | 2015-01-07 |
| ES2583231T3 (es) | 2016-09-19 |
| SG11201405129RA (en) | 2014-09-26 |
| CN104350054A (zh) | 2015-02-11 |
| EP2820020B1 (en) | 2016-04-06 |
| CA2865946A1 (en) | 2013-09-06 |
| CN104350054B (zh) | 2017-06-13 |
| MX2014010494A (es) | 2015-04-08 |
| AU2013224848A1 (en) | 2014-08-28 |
| RU2014139705A (ru) | 2016-04-20 |
| US20150018329A1 (en) | 2015-01-15 |
| MX347359B (es) | 2017-04-06 |
| KR20140131994A (ko) | 2014-11-14 |
| BR112014021189B1 (pt) | 2022-08-16 |
| US9567345B2 (en) | 2017-02-14 |
| HUE029264T2 (en) | 2017-02-28 |
| AU2013224848B2 (en) | 2017-06-29 |
| CA2865946C (en) | 2020-01-21 |
| RU2645347C2 (ru) | 2018-02-21 |
| JP6182549B2 (ja) | 2017-08-16 |
| ZA201406078B (en) | 2016-08-31 |
| EP2634190A1 (en) | 2013-09-04 |
| HK1206014A1 (en) | 2015-12-31 |
| DK2820020T3 (en) | 2016-07-04 |
| IL234183A (en) | 2016-11-30 |
| BR112014021189A2 (https=) | 2017-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101821452B1 (ko) | 선택성 사이클린-의존성 키나제 저해제로서 피라졸로-트리아진 유도체 | |
| US9096608B2 (en) | Pharmaceutically active pyrazolo-triazine derivatives | |
| CN102933561B (zh) | 具有药学活性的二取代三嗪衍生物 | |
| CN103562184B (zh) | 药学活性的二取代的吡啶衍生物 | |
| WO2021175270A1 (zh) | 新型hpk1抑制剂及其制备方法和应用 | |
| EP1789393A2 (en) | Pyridinylamines | |
| KR20090091353A (ko) | Ｍａｐｋ／ｅｒｋ 키나아제 억제제 | |
| US12240828B2 (en) | Heteroaromatic compounds as vanin inhibitors | |
| CA2897459C (en) | Heterocyclic amide derivatives as p2x7 receptor antagonists | |
| AU2005245536A1 (en) | Substituted azachinazolines having an antiviral action | |
| HK1206014B (en) | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors | |
| HK1181771B (en) | Pharmaceutically active disubstituted triazine derivatives | |
| HK1193813B (en) | Pharmaceutically active disubstituted pyridine derivatives | |
| HK1192470A (en) | Pharmaceutically active disubstituted triazine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PA0302 | Request for accelerated examination |
St.27 status event code: A-1-2-D10-D17-exm-PA0302 St.27 status event code: A-1-2-D10-D16-exm-PA0302 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 9 |